Posted by Michael Wonder on 13 Feb 2023
Ocuphire announces FDA acceptance of new drug application and PDUFA date of 28 September 2023 for Nyxol eye drops for reversal of mydriasis
13 February 2023 - If approved later this year, Nyxol could be the only commercially available eye drop for reversal of dilation.
Ocuphire Pharma today announced that the US FDA has accepted the new drug application for Nyxol (phentolamine ophthalmic 0.75$ solution eye drops) for the treatment of pharmacologically-induced mydriasis.
